-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Advanced bladder cancer is aggressive and patients generally have a poor
When people develop cancer, a type of immune cell called a "natural killer cell" starts to act in an attempt to kill tumor cells
To make more killer cells, the researchers showed that they could induce CD8+ T cells to express a molecule called NKG2A on their surface, making them behave more like natural killer cells
The second finding was about the ability
"These findings suggest that blocking antibodies to NKG2A and PD-L1 may be a more effective treatment strategy for patients with bladder cancer tumors with high levels of HLA-E and NKG2A-positive CD8+ T cells," said Lead and co-corresponding author Dr.
"Immune checkpoint blockade is a major cancer immunotherapy that targets the PD1-PDL1 pathway to reactivate 'depleted' CD8+ T cells to fight tumors," said
To conduct the study, the researchers analyzed the tumors and blood of patients with bladder cancer at different stages and studied all specimens that were taken immediately after the patients' surgery to ensure that they were able to capture live immune cells and examine their function
NKG2A and HLA-E define an alternative immune checkpoint axis in bladder cancer.
